** Clarity Pharmaceuticals CU6.AX rises as much as 5.6% to A$7.6, its highest since Oct. 9
** Co signs agreement with U.S.-based firm Nucleus Radiopharma to produce their Cu-SAR-bisPSMA drug for the imaging and treatment of prostate cancer
** Says agreement to expand production anticipating recruitment demand for drug's phase II and phase III trials
** Stock posts largest intraday pct gain since Oct. 25
** YTD, CU6 has nearly tripled
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.